Gapping down
In reaction to disappointing earnings/guidance:
- RH -11.5%, VFF -11.3%, CRON -5.4%, BNTX -2.4%
Other news:
- AMRN -70.7% (reports of an unfavorable patent ruling for Vascepa)
- SVRA -7.7% (terminates enrollment in Phase 3 AVAIL and Phase 2a ENCORE studies due to COVID-19)
- BBX -6.3% (drew down $60.0 mln under its $125.0 million revolving credit facility on March 19)
- DPZ -5.7% (says Q1 comps were +1.6% at US stores, US sales were impacted by many factors)
- HIBB -5.5% (names Robert Volke as CFO)
- RETA -4.9% (provides COVID-19 update in connection with clinical programs; to stop Phase 3 CATALYST study)
- ADC -4.6% (commences public offering of 2.5 mln shares)
- CODX -4.5% (discloses it does not anticipate using its emergency COVID-19 tests in the near future )
- LC -3.5% (provides update on effects of the coronavirus)
- CCL -3.5% (Carnival and Carnival plc (CUK) commenced an underwritten public offering of $1.25 billion of shares of common stock of the Corporation)
- PDM -1.5% (still evaluating impact on the co's earnings projection)
Analyst comments:
- TWLO -2.2% (downgraded to Neutral from Overweight at Piper Sandler)
- COUP -1.2% (downgraded to Neutral from Overweight at Piper Sandler)